Zhenhua Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhenhua Chen has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Jianjun Chen
Department of Systems Biology, Beckman Research Institute of City of Hope, Monrovia, USA
22 shared publications - Guido Marcucci
Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope Medical Center, Duarte, USA
19 shared publications - Lucy Y. Ghoda
Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, USA
15 shared publications - Lili Wang
Department of Systems Biology, Beckman Research Institute, City of Hope, Duarte, USA
12 shared publications - Steven Terry Rosen
Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA 91010, USA
12 shared publications - Aijun Liao
Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China
11 shared publications
Latest Publications
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF19
The HDAC8–U2AF1 Axis Dysregulates DNA Damage–Responsive RNA Splicing and Creates Targetable Vulnerabilities in Acute Myeloid Leukemia
Despite recent treatment advances using targeted therapies, acute myeloid leukemia (AML) remains a highly lethal disease. Mechanism-based biomarker-informed therapies could expand therapeutic options and enable rational combination strategies. In this study, we demonstrated that HDAC8 impairs DNA repair and confers therapeutic vulnerabilities in AML. Analysis of datasets of patients with AML revealed that HDAC8 is overexpressed in more than half of cases and is associated with dysregulated DNA damage response (DDR) gene expression. Elevated HDAC8 expression induced DNA damage phenotypes and compromised homologous recombination (HR)–mediated repair. Mechanistically, HDAC8 regulated acetylation of the splicing factor U2AF1, which blocked DNA repair by regulating RNA splicing. In response to DNA damage, the acetyltransferase TIP60 acetylated U2AF1 at lysines 23 and 175, modifications required for the interaction of U2AF1 with BRCA1 and BCLAF1 within a DDR-associated spliceosomal complex. HDAC8 promoted the removal of these acetyl groups, disrupting U2AF1–BRCA1–BCLAF1 complex formation and altering DDR-associated RNA splicing. Consequently, HDAC8 hyperactivity drove widespread RNA splicing dysregulation, defective HR repair, and increased sensitivity to both splicing modulators and PARP inhibitors. In preclinical models, including patient-derived xenografts, the splicing modulator H3B-8800 and the PARP inhibitor talazoparib reduced leukemia burden and leukemia stem cell activity, with enhanced efficacy observed in combination. In inv(16)(p13q22) AML, the CBFβ::SMMHC fusion protein exploited the HDAC8–U2AF1 axis to promote genomic instability. These findings identify the HDAC8–U2AF1 axis as a mechanistic driver of DDR dysfunction and genomic instability and uncover actionable, biomarker-informed therapeutic vulnerabilities in HDAC8-high AML. Significance: HDAC8 regulates a U2AF1-mediated axis to drive RNA splicing dysregulation and DNA repair defects, revealing therapeutic vulnerabilities that can be exploited with spliceosome modulators and PARP inhibitors in acute myeloid leukemia.
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
- p. OF1-OF19
The HDAC8–U2AF1 Axis Dysregulates DNA Damage–Responsive RNA Splicing and Creates Targetable Vulnerabilities in Acute Myeloid Leukemia
Despite recent treatment advances using targeted therapies, acute myeloid leukemia (AML) remains a highly lethal disease. Mechanism-based biomarker-informed therapies could expand therapeutic options and enable rational combination strategies. In this study, we demonstrated that HDAC8 impairs DNA repair and confers therapeutic vulnerabilities in AML. Analysis of datasets of patients with AML revealed that HDAC8 is overexpressed in more than half of cases and is associated with dysregulated DNA damage response (DDR) gene expression. Elevated HDAC8 expression induced DNA damage phenotypes and compromised homologous recombination (HR)–mediated repair. Mechanistically, HDAC8 regulated acetylation of the splicing factor U2AF1, which blocked DNA repair by regulating RNA splicing. In response to DNA damage, the acetyltransferase TIP60 acetylated U2AF1 at lysines 23 and 175, modifications required for the interaction of U2AF1 with BRCA1 and BCLAF1 within a DDR-associated spliceosomal complex. HDAC8 promoted the removal of these acetyl groups, disrupting U2AF1–BRCA1–BCLAF1 complex formation and altering DDR-associated RNA splicing. Consequently, HDAC8 hyperactivity drove widespread RNA splicing dysregulation, defective HR repair, and increased sensitivity to both splicing modulators and PARP inhibitors. In preclinical models, including patient-derived xenografts, the splicing modulator H3B-8800 and the PARP inhibitor talazoparib reduced leukemia burden and leukemia stem cell activity, with enhanced efficacy observed in combination. In inv(16)(p13q22) AML, the CBFβ::SMMHC fusion protein exploited the HDAC8–U2AF1 axis to promote genomic instability. These findings identify the HDAC8–U2AF1 axis as a mechanistic driver of DDR dysfunction and genomic instability and uncover actionable, biomarker-informed therapeutic vulnerabilities in HDAC8-high AML. Significance: HDAC8 regulates a U2AF1-mediated axis to drive RNA splicing dysregulation and DNA repair defects, revealing therapeutic vulnerabilities that can be exploited with spliceosome modulators and PARP inhibitors in acute myeloid leukemia.
- 26 June 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (6) , 944-963
Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics
De novo purine synthesis is required to maintain tumor growth; however, its impact on therapy resistance remains unclear. Here, through a dynamic BH3-priming-based CRISPR screen, we found that deletion of ADSS2, which encodes the adenylosuccinate synthase 2 enzyme essential for adenosine monophosphate (AMP) synthesis, re-sensitizes drug-resistant acute myeloid leukemia cells to venetoclax and a myeloid cell leukemia-1 (MCL1) inhibitor. Single-cell sequencing analysis of patient-derived xenograft samples revealed a positive association of high ADSS2 activity in TP53-mutant cells with poor responsiveness to venetoclax. We developed an ADSS2 antagonist, which synergized with BH3 mimetics to promote apoptosis in preclinical models. Mechanistically, sensitization mediated by ADSS2 targeting correlated with downregulated AMP-activated protein kinase activity, which in resistant cells promotes mitophagy to eliminate damaged mitochondria after BH3 mimetic treatment. These data show that AMP synthesis promotes BH3 mimetic resistance and that combining ADSS2 targeting with BH3 mimetics represents a promising anti-cancer approach.
- 26 June 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (6) , 944-963
Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics
De novo purine synthesis is required to maintain tumor growth; however, its impact on therapy resistance remains unclear. Here, through a dynamic BH3-priming-based CRISPR screen, we found that deletion of ADSS2, which encodes the adenylosuccinate synthase 2 enzyme essential for adenosine monophosphate (AMP) synthesis, re-sensitizes drug-resistant acute myeloid leukemia cells to venetoclax and a myeloid cell leukemia-1 (MCL1) inhibitor. Single-cell sequencing analysis of patient-derived xenograft samples revealed a positive association of high ADSS2 activity in TP53-mutant cells with poor responsiveness to venetoclax. We developed an ADSS2 antagonist, which synergized with BH3 mimetics to promote apoptosis in preclinical models. Mechanistically, sensitization mediated by ADSS2 targeting correlated with downregulated AMP-activated protein kinase activity, which in resistant cells promotes mitophagy to eliminate damaged mitochondria after BH3 mimetic treatment. These data show that AMP synthesis promotes BH3 mimetic resistance and that combining ADSS2 targeting with BH3 mimetics represents a promising anti-cancer approach.
- Top Cited Papers
- 5 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (10) , 1083-1097
Pharmacological inhibition of miR-126 enhances venetoclax activity in acute myeloid leukemia
Leukemic stem cells (LSCs) in acute myeloid leukemia (AML) depend on oxidative phosphorylation (OXPHOS) sustained by fatty acid oxidation (FAO) and mitochondrial fusion (mitofusion). In this study, we demonstrate that microRNA-126 (miR-126) maintains LSC function by promoting B-cell lymphoma 2 (BCL-2)–dependent FAO, OXPHOS, and mitofusion, whereas its inhibition disrupts mitochondrial metabolism, induces mitochondrial fission (mitofission), and triggers apoptosis. Mechanistically, miR-126 stabilizes BCL-2 through the SPRED1/extracellular signal-regulated kinase axis, which upregulates CPT1B (FAO) and NRF2 (antioxidant response) while regulating mitochondrial dynamics through DRP1 phosphorylation (inhibiting mitofission) and MFN1/2 phosphorylation (enhancing mitofusion). miRisten, a CpG-conjugated anti–miR-126 oligonucleotide now in clinical trials (NCT07025564), synergized with venetoclax (VEN) to suppress FAO/OXPHOS, promote mitofission, and impair LSC homeostasis. In vivo, miRisten potentiated the VEN/azacitidine regimen, an US Food and Drug Administration-approved therapy for older or unfit patients with AML, significantly prolonging survival in patient-derived xenograft models. VEN/miRisten combination also reduced LSC burden and restored VEN sensitivity, establishing miR-126 inhibition as a transformative therapeutic strategy for AML.
- 5 March 2026
- Published by American Society of Hematology in Blood
- Vol. 147 (10) , 1083-1097
Top Cited PapersPharmacological inhibition of miR-126 enhances venetoclax activity in acute myeloid leukemia
Leukemic stem cells (LSCs) in acute myeloid leukemia (AML) depend on oxidative phosphorylation (OXPHOS) sustained by fatty acid oxidation (FAO) and mitochondrial fusion (mitofusion). In this study, we demonstrate that microRNA-126 (miR-126) maintains LSC function by promoting B-cell lymphoma 2 (BCL-2)–dependent FAO, OXPHOS, and mitofusion, whereas its inhibition disrupts mitochondrial metabolism, induces mitochondrial fission (mitofission), and triggers apoptosis. Mechanistically, miR-126 stabilizes BCL-2 through the SPRED1/extracellular signal-regulated kinase axis, which upregulates CPT1B (FAO) and NRF2 (antioxidant response) while regulating mitochondrial dynamics through DRP1 phosphorylation (inhibiting mitofission) and MFN1/2 phosphorylation (enhancing mitofusion). miRisten, a CpG-conjugated anti–miR-126 oligonucleotide now in clinical trials (NCT07025564), synergized with venetoclax (VEN) to suppress FAO/OXPHOS, promote mitofission, and impair LSC homeostasis. In vivo, miRisten potentiated the VEN/azacitidine regimen, an US Food and Drug Administration-approved therapy for older or unfit patients with AML, significantly prolonging survival in patient-derived xenograft models. VEN/miRisten combination also reduced LSC burden and restored VEN sensitivity, establishing miR-126 inhibition as a transformative therapeutic strategy for AML.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-8 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-8 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-5 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-5 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S3 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Table S1: Effects of ALKBH1 KD on f5C34 in mitochondrial tRNA-Met Supplementary Table S2: Genetic background of the AML patient samples. Supplementary Table S3: List of oligonucleotide sequences
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S3 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Table S1: Effects of ALKBH1 KD on f5C34 in mitochondrial tRNA-Met Supplementary Table S2: Genetic background of the AML patient samples. Supplementary Table S3: List of oligonucleotide sequences
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Proteomics Data 1 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Quantitative proteomics after ALKBH1 knockdown in MOLM13 cells.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Proteomics Data 1 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Quantitative proteomics after ALKBH1 knockdown in MOLM13 cells.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S7 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Figure S1. ALKBH1 is required for human AML cell survival/growth in vitro and human AML progression in vivo. Supplementary Figure S2. ALKBH1 is required for leukemic cell transformation, LSC/LIC self-renewal and AML maintenance. Supplementary Figure S3. ALKBH1 is dispensable for normal hematopoiesis. Supplementary Figure S4. ALKBH1 is required for mitochondrial functions in AML cells. Supplementary Figure S5. ALKBH1 specifically catalyzes the conversion of m5C/m5Cm to f5C in tRNAs and is crutial for protein translation in AML. Supplementary Figure S6. WDR43 is a direct target of ALKBH1 through tRNA f5C-mediaed codon biased translation and phenocopies the functions of ALKBH1 in AML. Supplementary Figure S7. Discovery of the ALKBH1/WDR43/BCL2 axis and the synergistic effect of targeting ALKBH1/WDR43/BCL2 axis together with venetoclax in treating AML.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S7 from ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Supplementary Figure S1. ALKBH1 is required for human AML cell survival/growth in vitro and human AML progression in vivo. Supplementary Figure S2. ALKBH1 is required for leukemic cell transformation, LSC/LIC self-renewal and AML maintenance. Supplementary Figure S3. ALKBH1 is dispensable for normal hematopoiesis. Supplementary Figure S4. ALKBH1 is required for mitochondrial functions in AML cells. Supplementary Figure S5. ALKBH1 specifically catalyzes the conversion of m5C/m5Cm to f5C in tRNAs and is crutial for protein translation in AML. Supplementary Figure S6. WDR43 is a direct target of ALKBH1 through tRNA f5C-mediaed codon biased translation and phenocopies the functions of ALKBH1 in AML. Supplementary Figure S7. Discovery of the ALKBH1/WDR43/BCL2 axis and the synergistic effect of targeting ALKBH1/WDR43/BCL2 axis together with venetoclax in treating AML.
- Open Access
- 15 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (33) , eadv7648
FTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia
Targeting ribosome biogenesis and protein translation has emerged as a promising avenue for cancer therapy. The fat mass and obesity-associated protein (FTO), an RNA N 6 -methyladenosine (m 6 A) eraser, has been identified as an oncogenic factor in acute myeloid leukemia (AML). Here, we present the development of an FTO degrader that selectively degrades FTO in AML cells, demonstrating superior efficacy both in vitro and in vivo. We confirmed that FTO degradation increases m 6 A modifications on mRNAs associated with ribosome biogenesis, promoting their YTHDF2-mediated decay. This disruption of ribosome biogenesis and protein translation contributes to the inhibition of AML progression. Our findings highlight this FTO degrader as a valuable tool compound for elucidating the functional roles of FTO in cancer and as a potential foundation for the development of selective anticancer therapies.
- 15 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (33) , eadv7648
Open AccessFTO degrader impairs ribosome biogenesis and protein translation in acute myeloid leukemia
Targeting ribosome biogenesis and protein translation has emerged as a promising avenue for cancer therapy. The fat mass and obesity-associated protein (FTO), an RNA N 6 -methyladenosine (m 6 A) eraser, has been identified as an oncogenic factor in acute myeloid leukemia (AML). Here, we present the development of an FTO degrader that selectively degrades FTO in AML cells, demonstrating superior efficacy both in vitro and in vivo. We confirmed that FTO degradation increases m 6 A modifications on mRNAs associated with ribosome biogenesis, promoting their YTHDF2-mediated decay. This disruption of ribosome biogenesis and protein translation contributes to the inhibition of AML progression. Our findings highlight this FTO degrader as a valuable tool compound for elucidating the functional roles of FTO in cancer and as a potential foundation for the development of selective anticancer therapies.
- 4 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (11) , 2298-2325
ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Cancer cells utilize codon-biased translation to fuel tumorigenesis and drug resistance; however, underlying mechanisms remain poorly understood. In this study, we show that ALKBH1 is overexpressed in acute myeloid leukemia (AML) and essential for leukemia stem cell/leukemia-initiating cell self-renewal and AML development/maintenance but dispensable for normal hematopoiesis. ALKBH1 enhances mitochondrial assembly/function and oxidative phosphorylation, crucial for AML survival/proliferation and resistance to venetoclax, a potent BCL2 inhibitor and widely used first-line targeted therapy for AML in the clinic. Mechanistically, ALKBH1 catalyzes 5-formylcytosine at tRNA wobble positions, reprograming decoding and facilitating codon-biased translation, a mechanism we term “epitranslatomic Midas touch,” which in turn drives leukemogenesis and drug resistance by promoting the synthesis of key oncogenic proteins like WDR43. Targeting ALKBH1, particularly together with venetoclax, exhibited potent antileukemia efficacy in preclinical models with favorable safety profiles. Collectively, our findings elucidate ALKBH1’s pivotal role in codon-biased translation and tumorigenesis and propose a novel therapeutic strategy for cancer treatment. Significance: This study uncovers that ALKBH1-driven tRNA-decoding reprogramming and codon-biased translation, termed “epitranslatomic Midas touch,” is crucial for leukemogenesis, leukemia stem cell/leukemia-initiating cell self-renewal, mitochondria structure/function, and resistance to venetoclax. Targeting ALKBH1, especially in combination with venetoclax, offers a promising therapeutic strategy to combat drug resistance in AML and potentially other ALKBH1-overexpressing cancers.
- 4 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (11) , 2298-2325
ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation
Cancer cells utilize codon-biased translation to fuel tumorigenesis and drug resistance; however, underlying mechanisms remain poorly understood. In this study, we show that ALKBH1 is overexpressed in acute myeloid leukemia (AML) and essential for leukemia stem cell/leukemia-initiating cell self-renewal and AML development/maintenance but dispensable for normal hematopoiesis. ALKBH1 enhances mitochondrial assembly/function and oxidative phosphorylation, crucial for AML survival/proliferation and resistance to venetoclax, a potent BCL2 inhibitor and widely used first-line targeted therapy for AML in the clinic. Mechanistically, ALKBH1 catalyzes 5-formylcytosine at tRNA wobble positions, reprograming decoding and facilitating codon-biased translation, a mechanism we term “epitranslatomic Midas touch,” which in turn drives leukemogenesis and drug resistance by promoting the synthesis of key oncogenic proteins like WDR43. Targeting ALKBH1, particularly together with venetoclax, exhibited potent antileukemia efficacy in preclinical models with favorable safety profiles. Collectively, our findings elucidate ALKBH1’s pivotal role in codon-biased translation and tumorigenesis and propose a novel therapeutic strategy for cancer treatment. Significance: This study uncovers that ALKBH1-driven tRNA-decoding reprogramming and codon-biased translation, termed “epitranslatomic Midas touch,” is crucial for leukemogenesis, leukemia stem cell/leukemia-initiating cell self-renewal, mitochondria structure/function, and resistance to venetoclax. Targeting ALKBH1, especially in combination with venetoclax, offers a promising therapeutic strategy to combat drug resistance in AML and potentially other ALKBH1-overexpressing cancers.